Sanofi’s lunsekimig hits primary and key secondary endpoints in phase 2 Asthma and CRSwNP trials

AI Briefing

• – Sanofi's lunsekimig shows promising results in Phase 2 trials for asthma and CRSwNP
• – The medication achieved dual TSLP/IL-13 blockade and demonstrated solid safety
• – Sanofi to proceed with further development of the treatment